6) There's also an extension study of the MYOFLAME-19 trial, which tested losartan (to relax blood vessels) and low-dose prednisolone (to calm the immune response) in COVID-19.
This substudy will focus on endothelial dysfunction and GPCR antibodies in post-COVID ME/CFS.